[O-46] Oral Session 46 Clinical trial and Regenerative medicine3

[O-46-5] EIGHTEEN-MONTH ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN IN THE ENVISION OPEN LABEL EXTENSION

^○Tomohide Adachi¹, David Kuter², Siobán Keel³, Charles Parker⁴, David C. Rees⁵, Ulrich Stölzel⁶, Paolo Ventura⁷, Manisha Balwani⁸, Laurent Gouya⁹, Amy Simon¹⁰, Shangbin Liu¹⁰, John Ko¹⁰, Sean Rhyee¹⁰, Samuel Silver¹¹ (1.General Internal medicine and Neurology, Tokyo Saiseikai central Hospital, Japan, 2.Massachusetts General Hospital, Boston, Massachusetts, USA;, 3.University of Washington, Seattle, Washington, USA, 4.University of Utah, Salt Lake City, Utah, USA, 5.King's College Hospital, United Kingdom, 6.Klinikum Chemnitz, Chemnitz, Germany, 7.Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 8.Icahn School of Medicine at Mt. Sinai, New York, New York, USA, 9.Centre Français des Porphyries, Paris, France, 10.Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA, 11.University of Michigan, Ann Arbor, Michigan, USA)